Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Artemis and Schering To Cooperate

By Pharmaceutical Processing | November 30, 2004

COLOGNE, Germany (November 29, 2004) – Artemis Pharmaceuticals GmbH, here, and Schering AG, Berlin, have signed an agreement to cooperate in mouse genetics and genomics. Financial details were not disclosed.

Under the agreement, Artemis will generate various genetically engineered mouse models for Schering. Schering will use the mice in its drug discovery research activities to identify novel compounds and therapies for the treatment of severe diseases.

The generation of the mouse models will be based on Artemis’ proprietary ArteMice and ArteMice Conditional technologies, which allow the rapid, efficient and reproducible generation of complex genetically modified mice for use in drug discovery research.

In particular the technologies allow the functional analysis of genes, in an in vivo setting, to determine the role such genes play in disease processes and disease therapy.

Peter Stadler, managing director of Artemis, termed the agreement “scientifically and economically important for Artemis.

Artemis, a wholly owned subsidiary of Exelixis Inc., South SanFrancisco, CA, provides “ready made” and “custom built” mice to pharmaceutical and biotechnology companies for drug discovery research as well as to academic centers for basic research purposes.

Artemis also cooperates with Merck, Inc., Sanofi-Aventis, Bayer AG, BoehringerIngelheim, Biovitrum AB, Evotec Neurosciences, Regeneron Pharmaceuticals,Acceleron Pharma, Benitec, Exelixis, the German Cancer Research Center(DKFZ) and others.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE